India Pharma Outlook Team | Tuesday, 10 March 2026
Pfizer said its experimental eczema drug tilrekimig has achieved its main goal in a mid-stage clinical study, marking an important step toward bringing a new treatment option for patients with moderate to severe atopic dermatitis.
The company reported that the eczema drug met the primary endpoint in a Phase 2 trial, showing significant improvement in symptoms compared with placebo.
The study evaluated tilrekimig in adults with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition that causes severe itching, redness, and skin damage. After 16 weeks of treatment, a higher proportion of patients taking the drug achieved EASI-75, which represents at least a 75% reduction in eczema severity.
Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies
Results from the trial showed placebo-adjusted response rates of 38.7% in the low-dose group, 51.9% in the middle-dose group, and 49.4% in the high-dose group. The treatment was generally well tolerated, and the safety profile was similar to placebo, with only a few serious adverse events reported and none linked to the drug.
Tilrekimig is designed as a trispecific antibody that blocks three inflammatory pathways involved in immune-driven diseases. It targets interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP), which play a key role in conditions driven by type-2 inflammation. Researchers believe this multi-target approach could improve outcomes compared with existing biologic therapies.
Pfizer said the encouraging results have prompted plans to advance the eczema drug into Phase 3 trials, with a pivotal late-stage study expected to begin this year. If the larger trials confirm the findings, the therapy could strengthen the company’s pipeline and expand treatment choices for patients living with chronic eczema.
The development comes as drugmakers compete in a growing global market for advanced eczema therapies, where biologic treatments have already transformed care for patients with severe disease.
